New England Journal of Medicine Publishes Results of Ebola Clinical Trial Confirming Superiority of Regeneron's REGN-EB3 to ZMapp in Preventing Ebola Deaths

[In The News]

TARRYTOWN, N.Y., Nov. 27, 2019 /PRNewswire/ -- Nearly 90 percent survival for patients who received REGN-EB3 treatment earlier in the course of their disease; 66.5 percent survival among all patients who received REGN-EB3 Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) announced today that...

View the full article